Abstract
Data on comparative safety of opioid analgesics are limited, but some reports suggest disproportionate mortality risk associated with methadone. Our objective was to compare mortality rates among patients who received prescribed methadone or long-acting morphine for pain. This is a retrospective observational cohort drawn from Department of Veterans Affairs (VA) health care databases, January 1, 2000, to December 31, 2007. We included 28,554 patients who received methadone and 79,938 who received long-acting morphine from VA pharmacies. Compared with those who received long-acting morphine, patients who received methadone were younger, less likely to have some medical comorbidities, and more likely to have psychiatric and substance use disorders. Patients were stratified into quintiles according to propensity score; the probability of receiving methadone was conditional on demographic, clinical, and VA service area variables. Overall propensity-adjusted mortality was lower for methadone than for morphine. Hazard ratios varied across propensity score quintiles; the magnitude of the between-drug difference in mortality decreased as the propensity to receive methadone increased. Mortality was significantly lower for methadone in all but the last quintile, in which there was no between-drug difference in mortality (hazard ratio = 0.92, 95% confidence interval = 0.74, 1.16). Multiple sensitivity analyses found either no difference in mortality between methadone and long-acting morphine or lower mortality rates among patients who received methadone. In summary, we found no evidence of excess all-cause mortality among VA patients who received methadone compared with those who received long-acting morphine. Randomized trials and prospective observational research are needed to better understand the relative safety of long-acting opioids. Among patients who received methadone or long-acting morphine for pain from Department of Veterans Affairs pharmacies in 2000-2007, no evidence of excess all-cause mortality associated with methadone was found.
| Original language | English |
|---|---|
| Pages (from-to) | 1789-1795 |
| Number of pages | 7 |
| Journal | Pain |
| Volume | 152 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2011 |
Fingerprint
Keywords
- Methadone
- Morphine
- Mortality
- Opioid analgesics
ASJC Scopus subject areas
- Clinical Neurology
- Anesthesiology and Pain Medicine
- Neurology
- Pharmacology
Cite this
Comparative mortality among Department of Veterans Affairs patients prescribed methadone or long-acting morphine for chronic pain. / Krebs, Erin E.; Becker, William C.; Zerzan, Judy; Bair, Matthew; McCoy, Kimberly; Hui, Siu.
In: Pain, Vol. 152, No. 8, 08.2011, p. 1789-1795.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparative mortality among Department of Veterans Affairs patients prescribed methadone or long-acting morphine for chronic pain
AU - Krebs, Erin E.
AU - Becker, William C.
AU - Zerzan, Judy
AU - Bair, Matthew
AU - McCoy, Kimberly
AU - Hui, Siu
PY - 2011/8
Y1 - 2011/8
N2 - Data on comparative safety of opioid analgesics are limited, but some reports suggest disproportionate mortality risk associated with methadone. Our objective was to compare mortality rates among patients who received prescribed methadone or long-acting morphine for pain. This is a retrospective observational cohort drawn from Department of Veterans Affairs (VA) health care databases, January 1, 2000, to December 31, 2007. We included 28,554 patients who received methadone and 79,938 who received long-acting morphine from VA pharmacies. Compared with those who received long-acting morphine, patients who received methadone were younger, less likely to have some medical comorbidities, and more likely to have psychiatric and substance use disorders. Patients were stratified into quintiles according to propensity score; the probability of receiving methadone was conditional on demographic, clinical, and VA service area variables. Overall propensity-adjusted mortality was lower for methadone than for morphine. Hazard ratios varied across propensity score quintiles; the magnitude of the between-drug difference in mortality decreased as the propensity to receive methadone increased. Mortality was significantly lower for methadone in all but the last quintile, in which there was no between-drug difference in mortality (hazard ratio = 0.92, 95% confidence interval = 0.74, 1.16). Multiple sensitivity analyses found either no difference in mortality between methadone and long-acting morphine or lower mortality rates among patients who received methadone. In summary, we found no evidence of excess all-cause mortality among VA patients who received methadone compared with those who received long-acting morphine. Randomized trials and prospective observational research are needed to better understand the relative safety of long-acting opioids. Among patients who received methadone or long-acting morphine for pain from Department of Veterans Affairs pharmacies in 2000-2007, no evidence of excess all-cause mortality associated with methadone was found.
AB - Data on comparative safety of opioid analgesics are limited, but some reports suggest disproportionate mortality risk associated with methadone. Our objective was to compare mortality rates among patients who received prescribed methadone or long-acting morphine for pain. This is a retrospective observational cohort drawn from Department of Veterans Affairs (VA) health care databases, January 1, 2000, to December 31, 2007. We included 28,554 patients who received methadone and 79,938 who received long-acting morphine from VA pharmacies. Compared with those who received long-acting morphine, patients who received methadone were younger, less likely to have some medical comorbidities, and more likely to have psychiatric and substance use disorders. Patients were stratified into quintiles according to propensity score; the probability of receiving methadone was conditional on demographic, clinical, and VA service area variables. Overall propensity-adjusted mortality was lower for methadone than for morphine. Hazard ratios varied across propensity score quintiles; the magnitude of the between-drug difference in mortality decreased as the propensity to receive methadone increased. Mortality was significantly lower for methadone in all but the last quintile, in which there was no between-drug difference in mortality (hazard ratio = 0.92, 95% confidence interval = 0.74, 1.16). Multiple sensitivity analyses found either no difference in mortality between methadone and long-acting morphine or lower mortality rates among patients who received methadone. In summary, we found no evidence of excess all-cause mortality among VA patients who received methadone compared with those who received long-acting morphine. Randomized trials and prospective observational research are needed to better understand the relative safety of long-acting opioids. Among patients who received methadone or long-acting morphine for pain from Department of Veterans Affairs pharmacies in 2000-2007, no evidence of excess all-cause mortality associated with methadone was found.
KW - Methadone
KW - Morphine
KW - Mortality
KW - Opioid analgesics
UR - http://www.scopus.com/inward/record.url?scp=79960440685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960440685&partnerID=8YFLogxK
U2 - 10.1016/j.pain.2011.03.023
DO - 10.1016/j.pain.2011.03.023
M3 - Article
C2 - 21524850
AN - SCOPUS:79960440685
VL - 152
SP - 1789
EP - 1795
JO - Pain
JF - Pain
SN - 0304-3959
IS - 8
ER -